This study is for hospitalized adults with suspected or confirmed infections who are being treated with vancomycin. Researchers want to compare the risk of acute kidney injury (AKI) when vancomycin is given with either piperacillin-tazobactam or cefepime. Both combinations are commonly used, but there's a question about whether one might be safer for your kidneys. The study will measure a specific marker in your blood called Serum Cystatin C Concentration to see how your kidneys are doing. The goal is to understand which combination might be less likely to cause kidney problems. The study aims to enroll 750 participants, but its current status is unclear.

Study design

This is an interventional study comparing two standard antibiotic combinations. It aims to enroll 750 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your Serum Cystatin C Concentration will be measured 5 days after you join the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.